Saturday, 4 January 2020

Daratumumab involved in risk of reactivation of hepatitis B virus

The Medicines and Healthcare Products Regulatory Agency (MHRA) London has announced that the product information for daratumumab will be updated to include the risk of reactivation of hepatitis B virus (HBV).



source https://www.pharmatutor.org/pharma-news/2020/daratumumab-involved-in-risk-of-reactivation-of-hepatitis-b-virus
at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Pharmaceutical jobs for MPharm / MSc / BPharm or BSc - DPharm or PharmD and PhD

  Openings for Pharmacists under the National Health Mission Degree or Diploma in Pharmacy (50%) & Registration in CG Pharmacy Registrat...